Examkin

Question

Difficulty: HardGenetic and Molecular Mechanisms

A 24-year-old woman is brought to the emergency department by her husband due to severe, diffuse abdominal pain, nausea, and confusion for the past 24 hours. She has a history of a seizure disorder, for which she was recently started on phenytoin by her new primary care physician. She also reports that her urine has turned a dark, reddish-brown color since yesterday. Physical examination reveals tachycardia, diminished bowel sounds, and diffuse abdominal tenderness without rebound or guarding. Neurologic examination shows grade 3/53/5 motor strength in the proximal upper extremities. Laboratory studies reveal a normal complete blood count and comprehensive metabolic panel. A urine test shows significantly elevated levels of porphobilinogen. Which of the following best describes the underlying genetic and molecular mechanism responsible for this patient's acute presentation?

  1. A
    Toxic accumulation of a medication due to competitive inhibition of cytochrome P450 metabolic pathways.
  2. B
    Missense mutation resulting in a dominant negative structural protein that requires targeted genetic sequencing for diagnosis.
  3. Haploinsufficiency of a biosynthetic enzyme unmasked by transcriptional upregulation of a rate-limiting enzyme.Answer
  4. D
    Autosomal recessive deficiency of a lysosomal hydrolase leading to toxic accumulation of metabolic byproducts.
  5. E
    Idiopathic autoimmune destruction of a physiologic receptor triggered by recent pharmacologic exposure.

Answer

Haploinsufficiency of a biosynthetic enzyme unmasked by transcriptional upregulation of a rate-limiting enzyme.
The correct answer accurately describes the pathogenesis of acute intermittent porphyria (AIP). AIP is an autosomal dominant condition characterized by a partial deficiency (haploinsufficiency) of porphobilinogen deaminase (also known as hydroxymethylbilane synthase). Under baseline conditions, patients are typically asymptomatic because 50%50\% enzyme activity is sufficient for normal physiologic needs. However, exposure to cytochrome P450 inducers, such as phenytoin, increases hepatic consumption of heme. This causes a loss of negative feedback on delta-aminolevulinic acid synthase 1 (ALAS1), the rate-limiting enzyme of the pathway. The subsequent transcriptional upregulation of ALAS1 increases metabolite flux, which overwhelms the partially deficient enzyme downstream, leading to the toxic accumulation of porphobilinogen (PBG) and aminolevulinic acid (ALA) that cause the neurovisceral symptoms.

Step-by-Step Solution

1
Identify the clinical syndrome based on the presentation and laboratory findings.
The combination of severe abdominal pain, neurologic symptoms (confusion, proximal weakness), reddish-brown urine, and elevated porphobilinogen (PBG) establishes the diagnosis of acute intermittent porphyria (AIP).
Recognizing the classic triad of neurovisceral symptoms and the specific biochemical marker (PBG) is necessary to determine the correct disease process.
2
Determine the genetic inheritance pattern and molecular mechanism of the disease.
AIP is an autosomal dominant disorder caused by a heterozygous mutation in the HMBS gene (encoding porphobilinogen deaminase), leading to haploinsufficiency where the patient retains only 50%50\% of normal enzyme activity.
Understanding that a single functional allele is insufficient under high-demand physiological states is the key to the pathogenesis of the condition.
3
Analyze the role of the newly started medication in precipitating the acute attack.
Phenytoin is a cytochrome P450 inducer that increases hepatic heme demand, leading to the compensatory transcriptional upregulation of delta-aminolevulinic acid synthase (ALAS1), the rate-limiting enzyme in heme biosynthesis.
The increased flux through the heme pathway overwhelms the partially deficient PBG deaminase enzyme, causing a toxic accumulation of upstream metabolites (ALA and PBG) that mediate the clinical symptoms.

Key Concept

Acute intermittent porphyria involves haploinsufficiency of porphobilinogen deaminase, which becomes clinically apparent when CYP450 inducers (e.g., phenytoin) upregulate ALAS1, overwhelming the pathway and causing toxic metabolite accumulation.
Rate this question

Topics

Genetic and Molecular Mechanisms

More questions from this topic